Deciphering breast cancer: from biology to the clinic
E Nolan, GJ Lindeman, JE Visvader - Cell, 2023 - cell.com
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Abstract The AURORA US Metastasis Project was established with the goal to identify
molecular features associated with metastasis. We assayed 55 females with metastatic …
molecular features associated with metastasis. We assayed 55 females with metastatic …
[HTML][HTML] Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …
[HTML][HTML] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Final …
Background Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA
mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth …
mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth …
Clinical cancer genomic profiling
D Chakravarty, DB Solit - Nature Reviews Genetics, 2021 - nature.com
Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets
Metastatic and locally-advanced neuroendocrine neoplasms (aNEN) form clinically and
genetically heterogeneous malignancies, characterized by distinct prognoses based upon …
genetically heterogeneous malignancies, characterized by distinct prognoses based upon …
Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution
S Venkatesan, M Angelova, C Puttick, H Zhai… - Cancer discovery, 2021 - AACR
APOBEC3 enzymes are cytosine deaminases implicated in cancer. Precisely when
APOBEC3 expression is induced during cancer development remains to be defined. Here …
APOBEC3 expression is induced during cancer development remains to be defined. Here …